Sensei Biotherapeutics to Present Preclinical Data on SNS-103 at the CRI-ENCI Eighth International Immunotherapy Conference
Sensei Biotherapeutics (Nasdaq: SNSE) announced that it will present preclinical data on SNS-103 at the CRI-ENCI Eighth International Immunotherapy Conference from September 8-11, 2024. The presentation, titled 'Pre-clinical characterization of monoclonal antibodies targeting CD39 activity in the acidic tumor microenvironment,' will be given by F. Donelson Smith, Ph.D., Senior Director of Biologics Discovery & Early Development. The poster session is scheduled for September 8, 2024, from 12:05 – 2:05 p.m. EDT.
Sensei Biotherapeutics is a clinical-stage immuno-oncology company focused on developing next-generation cancer therapeutics. The presentation of preclinical data on SNS-103 suggests ongoing research and development efforts in their pipeline.
Sensei Biotherapeutics (Nasdaq: SNSE) ha annunciato che presenterà dati preclinici su SNS-103 alla CRI-ENCI Eighth International Immunotherapy Conference dal 8 all'11 settembre 2024. La presentazione, intitolata 'Caratterizzazione pre-clinica degli anticorpi monoclonali che mirano all'attività di CD39 nell'ambiente tumorale acido,' sarà tenuta da F. Donelson Smith, Ph.D., Direttore Senior della Scoperta e Sviluppo Precoce dei Biologici. La sessione poster è programmata per il 8 settembre 2024, dalle 12:05 alle 14:05 EDT.
Sensei Biotherapeutics è un azienda di immuno-oncologia in fase clinica focalizzata nello sviluppo di terapie oncologiche di nuova generazione. La presentazione dei dati preclinici su SNS-103 suggerisce sforzi continui di ricerca e sviluppo nel loro pipeline.
Sensei Biotherapeutics (Nasdaq: SNSE) anunció que presentará datos preclínicos sobre SNS-103 en la CRI-ENCI Eighth International Immunotherapy Conference del 8 al 11 de septiembre de 2024. La presentación, titulada 'Caracterización preclínica de anticuerpos monoclonales dirigidos a la actividad de CD39 en el microambiente tumoral ácido,' será realizada por F. Donelson Smith, Ph.D., Director Senior de Descubrimiento de Biológicos y Desarrollo Temprano. La sesión de carteles está programada para el 8 de septiembre de 2024, de 12:05 a 14:05 EDT.
Sensei Biotherapeutics es una compañía de inmuno-oncología en etapa clínica centrada en el desarrollo de terapias oncológicas de nueva generación. La presentación de datos preclínicos sobre SNS-103 sugiere esfuerzos continuos en investigación y desarrollo en su pipeline.
센세이 바이오테라퓨틱스(Sensei Biotherapeutics, 나스닥: SNSE)는 2024년 9월 8일부터 11일까지 열리는 CRI-ENCI 제8회 국제 면역 요법 컨퍼런스에서 SNS-103에 대한 전임상 데이터를 발표할 예정이라고 발표했습니다. 세션 제목은 '산성 종양 미세 환경에서 CD39 활성을 표적으로 하는 단클론 항체의 전임상 특성화'이며, F. 도넬슨 스미스(F. Donelson Smith) 박사가 발표할 예정입니다. 포스터 세션은 2024년 9월 8일 오후 12시 5분부터 오후 2시 5분까지 EDT에서 예정되어 있습니다.
센세이 바이오테라퓨틱스는 차세대 암 치료제를 개발하는 데 중점을 둔 임상 단계 면역 종양학 회사입니다. SNS-103에 대한 전임상 데이터 발표는 파이프라인에서의 지속적인 연구 및 개발 노력을 제안합니다.
Sensei Biotherapeutics (Nasdaq: SNSE) a annoncé qu'il présentera des données précliniques sur SNS-103 lors de la CRI-ENCI Eighth International Immunotherapy Conference du 8 au 11 septembre 2024. La présentation, intitulée 'Caractérisation préclinique des anticorps monoclonaux ciblant l'activité de CD39 dans le microenvironnement tumoral acide,' sera faite par F. Donelson Smith, Ph.D., Directeur Senior de la Découverte et Développement Précoce des Biologiques. La session d'affichage est prévue pour le 8 septembre 2024, de 12h05 à 14h05 EDT.
Sensei Biotherapeutics est une entreprise d'immuno-oncologie en phase clinique axée sur le développement de thérapies contre le cancer de nouvelle génération. La présentation des données précliniques sur SNS-103 suggère que des efforts de recherche et développement sont en cours dans leur pipeline.
Sensei Biotherapeutics (Nasdaq: SNSE) gab bekannt, dass das Unternehmen präklinische Daten zu SNS-103 auf der CRI-ENCI Eighth International Immunotherapy Conference vom 8. bis 11. September 2024 präsentieren wird. Die Präsentation mit dem Titel 'Präklinische Charakterisierung von monoklonalen Antikörpern, die die CD39-Aktivität im sauren Tumormikroenvironment anvisieren,' wird von F. Donelson Smith, Ph.D., Senior Director für Biologics Discovery & Early Development, gehalten. Die Postersession ist für den 8. September 2024 von 12:05 bis 14:05 Uhr EDT vorgesehen.
Sensei Biotherapeutics ist ein unternehmensorientiertes Unternehmen der klinischen Immunonkologie, das sich auf die Entwicklung von Therapeutika der nächsten Generation zur Behandlung von Krebs spezialisiert. Die Präsentation der präklinischen Daten zu SNS-103 deutet auf anhaltende Forschungs- und Entwicklungsanstrengungen in ihrem Portfolio hin.
- Presentation of preclinical data on SNS-103 at a major international conference
- Ongoing research and development in immuno-oncology therapeutics
- None.
BOSTON, Sept. 04, 2024 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients, today announced that preclinical data on SNS-103 will be presented in a poster session at the CRI-ENCI Eighth International Immunotherapy Conference, being held September 8-11, 2024, at the Gaylord National Resort & Convention Center in National Harbor, MD.
Presentation Details:
CRI-ENCI Eighth International Cancer Immunotherapy Conference
Title: Pre-clinical characterization of monoclonal antibodies targeting CD39 activity in the acidic tumor microenvironment
Presenter: F. Donelson Smith, Ph.D., Senior Director, Biologics Discovery & Early Development
Poster Number: 195A
Date and time: Sunday, September 8, 2024, 12:05 – 2:05 p.m. EDT
About Sensei Biotherapeutics
Sensei Biotherapeutics (Nasdaq: SNSE) is a clinical stage immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients. Through its TMAb™ (Tumor Microenvironment Activated biologics) platform, Sensei develops conditionally active therapeutics designed to disable immunosuppressive signals or activate immunostimulatory signals selectively in the tumor microenvironment. Sensei’s lead investigational candidate is SNS-101, a conditionally active antibody designed to block the V-domain Ig suppressor of T cell activation (VISTA) checkpoint selectively within the low pH tumor microenvironment, where VISTA acts as a suppressor of T cells by binding the receptor PSGL-1. The company is also developing SNS-102, a conditionally active monoclonal antibody targeting V-Set and Immunoglobulin Domain Containing 4 (VSIG-4); SNS-103, a conditionally active monoclonal antibody targeting ecto-nucleoside triphosphate diphosphohydrolase-1 (ENTPDase1), also known as CD39; and SNS-201, a conditionally active VISTAxCD28 bispecific antibody consisting of a CD28 agonist arm and a pH-sensitive anti-VISTA arm. For more information, please visit www.senseibio.com, and follow the company on X @SenseiBio and LinkedIn.
Investor Contact:
Michael Biega
Senior Director, Investor Relations
Sensei Biotherapeutics
mbiega@senseibio.com
Media Contact:
Joyce Allaire
LifeSci Advisors
Jallaire@lifesciadvisors.com
FAQ
What is Sensei Biotherapeutics (SNSE) presenting at the CRI-ENCI conference?
When and where is Sensei Biotherapeutics (SNSE) presenting its preclinical data?
Who is presenting the preclinical data for Sensei Biotherapeutics (SNSE)?
What is the focus of Sensei Biotherapeutics' (SNSE) research?
